Certainly, in the current global obesity epidemic, IGFs have attracted attention for their potential role as a link between cancer and insulin resistance syndrome (46), a metabolic syndrome of increasing incidence that encompasses hyper/hypoinsulinemia, hyper/hypoglycemia, dyslipidemia and hypertension, with a marked increase in risk to develop diabetes mellitus, cardiovascular diseases, and cancer (710)
Adjuvant glucose-like peptide 1 receptor agonist therapy for suboptimal weight loss after bariatric surgery: a systematic review
The trial was halted after the original commercial sponsor inappropriately released preliminary findings of a confidential early analysis
Your daily NAD+ routine, wherever training takes you
"Why can't I lose weight?" We find out why, and fix it
Originally developed as a treatment for Type 2 diabetes, Semaglutide has been FDA-approved for weight loss in individuals with obesity